Is There a Role for Proton Therapy in the Treatment of Breast Cancer?

Locoregional management strategies have considerably evolved.  Considerable progress has been made in understanding which patients will benefit from radiation therapy and ways to administer treatment that maximize clinical benefit while minimizing toxicity; however, many controversies exist as we

Surgical Management of Breast Cancer, Including SABCS Updates

Locoregional management strategies have considerably evolved.

Adjuvant and Neoadjuvant Therapies for Early Stage Breast Cancer, Including SABCS Updates
Clinicians are challenged to stay up-to-date on new approaches and options for neoadjuvant /adjuvant systemic therapy so they can provide appropriate care using a shared decision making process with the patient, taking into account patient and disease characteristics including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.
Genetics/Familial Risk Assessment for Breast Cancer: Controversies and Evolving Principles

There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.

NCCN 2020 Congress Series™: Breast Cancer with Updates from 2019 San Antonio Breast Cancer Symposium

Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies.

Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of HER-2 Positive Breast Cancer
It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.
NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of HER-2 Positive Breast Cancer
It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer
Triple-negative breast cancer is an aggressive subtype that is associated with poor outcomes. Staying up-to-date on current and emerging treatment options is important to integrate new evidence-based data into their clinical practice and optimize patient outcomes.
PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing

The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

Pages

Subscribe to RSS - Breast Cancer